Trial Profile
Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Safety, Efficacy and Potential Pharmacokinetic Interaction of RDEA594 and Allopurinol in Gout Patients With an Inadequate Hypouricemic Response With Standard Doses of Allopurinol.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Lesinurad (Primary) ; Allopurinol
- Indications Gout
- Focus Therapeutic Use
- Sponsors Ardea Biosciences
- 07 Sep 2016 Status changed from active, no longer recruiting to completed.
- 15 Apr 2016 Patients on lesinurad 400 mg and lesinurad 600 mg had their dose changed to lesinurad 200 mg; Patients on allopurinol qd alone were discontinued after protocol amendment 16 dated 07 October 2015.
- 15 Apr 2016 Planned End Date changed from 1 Apr 2015 to 1 Jul 2016.